| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now.
|
|
Today’s Big NewsMay 1, 2025 |
| By Fraiser Kansteiner Just as Eli Lilly appeared to be gaining an edge over its metabolic medicine rival Novo Nordisk in the U.S. obesity market, Novo has locked in a new formulary access deal that could give its star weight loss drug Wegovy a major advantage over its Lilly counterpart. |
|
|
|
By Gabrielle Masson The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect against multiple strains of a pandemic-prone virus at once. The concept is one scientists have chased for decades to no avail and represents a shift away from the government prioritizing next-gen COVID-19 vaccines. |
By Conor Hale The current standard of care is monitoring the patient with regular check-ups, to see if they begin to develop chest pain or shortness of breath, before planning a valve replacement procedure. |
By Andrea Park After seeing its spending soar and net loss grow to over $90 million in the first quarter, Phathom Pharmaceuticals is making cost-cutting moves—including significant changes to its marketing department. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now.
|
|
By Angus Liu Moderna is extending its cost savings program into 2027 and targeting a cash breakeven point sometime in 2028 as the mRNA biotech faces multiple regulatory uncertainties around vaccines under the Trump administration. |
By Gabrielle Masson With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. |
By Andrea Park Dynavax is kicking off May’s Hepatitis Awareness Month with a new push to improve education around hepatitis B and the benefits of vaccination. |
By Zoey Becker The company posted 6% revenue growth during the quarter thanks to three launches. Looking forward, Biogen said it's insulated from potential pharmaceutical tariffs. |
By Nick Paul Taylor Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news of a delay to the expected approval of the vaccine in older adults. |
By Eric Sagonowsky It's not immediately clear if COVID-19 vaccine makers could meet the agency's new requirement in order to release their updated vaccines by the time virus circulation typically ramps up in the fall and winter. |
By Nick Paul Taylor Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor degrader R&D plan in the wake of mixed data. Arvinas disclosed the rethink alongside news that it is laying off one-third of its staff to cut costs and extend its cash runway. |
Fierce podcastsDon’t miss an episode |
| | Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Tuesday, May 20, 2025 | 11am ET / 8am PT This webinar will feature industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Register today to learn more.
|
|
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperIs your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
| |
|
